News Feed

Friday, August 17, 2018

By Will Boggs MD

NEW YORK (Reuters Health) - Risankizumab, a monoclonal antibody that binds to the p19 subunit of interleukin-23, is effective for treating moderate-to-severe plaque psoriasis, according to results from two phase 3 trials.

Wednesday, August 8, 2018

By Reuters Staff

NEW YORK (Reuters Health) - Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn's disease (CD), according to data from company-sponsored clinical trials.

Wednesday, August 1, 2018

By Reuters Staff

NEW YORK (Reuters Health) - Adolescents with acne are more likely to engage in self-injurious behavior than their clear-skinned peers, a small study from Turkey hints.

Friday, July 27, 2018

By Lisa Rapaport

(Reuters Health) - The recombinant zoster vaccine Shingrix prevents shingles, and if people do contract the virus, it reduces the severity of illness, two company-funded studies suggest.

Thursday, July 26, 2018

By Anne Harding

NEW YORK (Reuters Health) - Cutaneous adverse reactions to programmed cell death protein 1 (PD-1) inhibitors can occur months after treatment initiation, and can also arise after patients stop taking the drugs, new research shows.

Thursday, July 26, 2018

By Marilynn Larkin

NEW YORK (Reuters Health) - Expression of major histocompatibility complex (MHC) class I and class II proteins may help predict a patient's response to melanoma immunotherapy, researchers have found.

Thursday, July 19, 2018

By Scott Baltic

Wednesday, July 11, 2018

By Will Boggs MD

NEW YORK (Reuters Health) - Combined systemic and intratumoral human papillomavirus (HPV) vaccine administration resulted in complete regression of multiple cutaneous basaloid squamous cell carcinomas, according to a case report.

Tuesday, July 10, 2018

By Anne Harding